3
Working versus Retiring
The era of steady employment after
school or college, working until
retirement age and living out a dotage
is becoming less common. People
with HIV infection, especially those
diagnosed prior to the era of highly active
antiretroviral therapy (HAART), have
often worked only sporadically or have
retired early. Now that life expectancy has
increased, many are considering second
careers, going back to train or working
either full or part-time. Apart from the
obvious financial rewards, this can bring
physical, mental and social benefits.
There is robust evidence that ongoing
mental and physical activity throughout
life has a significant impact in prolonging
both quantity and quality of life. It is
nonetheless important to establish
a balance to ensure that continued
employment is not physically and
mentally stressful, and therefore
detrimental to health. Equally it is
important that retirement does not lead
to reduction in physical, mental and
social stimulation or isolation. Therefore
to a certain extent, each individual can
influence this process by what they do
and how they choose to live. Advanced
planning should include recognition and
acceptance of individual risks and regular
review of how personal lifestyle can be
improved. It is not possible to predict
the future but it is possible to plan for a
healthier old age. Research indicates that
only a proportion of longevity (length
of life) is genetically determined whilst
the bulk of it depends on lifestyle and
environmental factors (external factors
such as infections, sunlight or accidents,
for example).
Section 3: Le Patient 21
Qui doit être testé? ....................................................21
1. Dépistage HVB ..........................................................21
2. Dépistage HVC ..........................................................24
Réduction des risques .................................................26
Partenaires et membres de la famille ...................................26
Vaccination HVB ......................................................26
Section 4: Evaluation 28
Evaluation générale ...................................................28
Evaluation de l’infection au VHB ........................................31
Evaluation de l’infection au VHC ........................................31
Facteurs à considérer avant de commencer le traitement
1. Maladies autoimmunes .................................................31
2. Conditions concomitantes ...............................................32
3. Autres questions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .32
Section 5: Traitement 35
Traitement de l’hépatite B .............................................35
Traitement de l’hépatite C .............................................35
Recommandations pour la surveillance et le traitement .................36
Section 6: Further Information and Appendices
Liens Web et ressources ................................................38
Annexes ..............................................................39
Annexe 1 - Feuille de rapport FibroScan® ...................................39
Annexe 2 - Echelle hospitalière de mesure de l’anxiété et de la dépression .39
Annexe 3 - Test rapide de détection d’alcool ...............................39
Remerciements .......................................................40